The Interplay between Metabolism, PPAR Signaling Pathway, and CancerView this Special Issue
Review Article | Open Access
Laura La Paglia, Angela Listì, Stefano Caruso, Valeria Amodeo, Francesco Passiglia, Viviana Bazan, Daniele Fanale, "Potential Role of ANGPTL4 in the Cross Talk between Metabolism and Cancer through PPAR Signaling Pathway", PPAR Research, vol. 2017, Article ID 8187235, 15 pages, 2017. https://doi.org/10.1155/2017/8187235
Potential Role of ANGPTL4 in the Cross Talk between Metabolism and Cancer through PPAR Signaling Pathway
The angiopoietin-like 4 (ANGPTL4) protein belongs to a superfamily of secreted proteins structurally related to factors modulating angiogenesis known as angiopoietins. At first, ANGPTL4 has been identified as an adipokine exclusively involved in lipid metabolism, because of its prevalent expression in liver and adipose tissue. This protein regulates lipid metabolism by inhibiting lipoprotein lipase (LPL) activity and stimulating lipolysis of white adipose tissue (WAT), resulting in increased levels of plasma triglycerides (TG) and fatty acids. Subsequently, ANGPTL4 has been shown to be involved in several nonmetabolic and metabolic conditions, both physiological and pathological, including angiogenesis and vascular permeability, cell differentiation, tumorigenesis, glucose homoeostasis, lipid metabolism, energy homeostasis, wound healing, inflammation, and redox regulation. The transcriptional regulation of ANGPTL4 can be modulated by several transcription factors, including PPARα, PPARβ/δ, PPARγ, and HIF-1α, and nutritional and hormonal conditions. Several studies showed that high levels of ANGPTL4 are associated with poor prognosis in patients with various solid tumors, suggesting an important role in cancer onset and progression, metastasis, and anoikis resistance. Here, we have discussed the potential role of ANGPTL4 in mediating the cross talk between metabolic syndromes, such as diabetes and obesity, and cancer through regulation of its expression by PPARs.
1. Peroxisome Proliferator-Activated Receptors (PPARs): Structure and Functions
Peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription factors belonging to the steroid hormone receptor superfamily, identified for the first time in 1990 by Issemann and Green . There are three distinct PPAR subtypes, PPARα, PPARβ/δ (also known as PPARβ or PPARδ), and PPARγ, encoded by specific genes located on different chromosomes. Although these three members show a significant homology, they differ from each other for tissue distribution, affinity for ligands, and biological functions . All subtypes are activated by endogenous ligands and participate in the regulation of several genes involved in glucose and lipid metabolism. However, other specific PPAR actions are limited to specific tissue types [3, 4]. PPARα, the first PPAR to be cloned, is highly expressed in tissues characterized by elevated fatty acid oxidation such as liver, heart, skeletal muscle, brown adipose tissue, kidney, adrenal gland, and intestinal mucosa, where it plays a key role in the fatty acid catabolism [5, 6]. PPARβ/δ is expressed in most of human tissues, mainly in the liver, adipose tissue, skeletal muscle, heart, brain, kidney, skin, and intestine, characterized by an increased lipid metabolism. However, the function of this isoform remains to be elucidated [7–10]. PPARγ is highly expressed in white and brown adipose tissue (WAT and BAT) and plays a pivotal role in the regulation of adipogenesis, fat storage, and glucose metabolism [11–15]. In addition, PPARγ also regulates the expression of proinflammatory cytokines, such as tumor necrosis factor- (TNF-), as well as genes involved in insulin sensitivity. For this reason, PPARγ is the main target of thiazolidinediones (TZDs), a class of drugs used to improve lipid and glucose metabolism in type 2 diabetes [16, 17].
PPARs show a DNA binding domain (DBD) in the N-terminal and a ligand binding domain (LBD) in the C-terminal separated by a hinge region acting as a docking site for cofactors . Three PPAR isoforms exhibit an 80% homology and are more divergent in the LBD, confirming their different response to various ligands. After activation by endogenous or synthetic ligands, PPARs undergo a conformational change that causes the translocation to the nucleus and the heterodimerization with another nuclear receptor, the retinoid X receptor (RXR) . The PPAR-RXR heterodimer then binds a DNA portion in the promoter region of target genes, called peroxisome proliferator response element (PPRE), modulating the expression of several genes involved in different physiological or pathological processes . Interestingly, the PPAR functions also depend on the binding with different coactivator and corepressor proteins . Indeed, after interaction with agonists, the conformational change of the PPAR structure causes also the attachment of coactivators and detachment of corepressors. Usually, PPAR-RXR heterodimers are packed with a corepressor molecule in PPRE and the binding with ligands causes an exchange of corepressors for coactivators. One of the more studied PPAR corepressors is histone deacetylase (HDAC). Among the different coactivators, there are PGC-1, p300, and CREB that are involved in regulation of metabolism as well as in cancer development [22, 23] (Figure 1).
2. Angiopoietin-Like 4 (ANGPTL4): Structure and Expression Patterns
The angiopoietin-like 4 (ANGPTL4) protein was discovered for the first time in 2000 by three independent research groups. They simultaneously identified this molecule as a fasting-induced adipose factor (Fiaf) in different tissues. ANGPTL4 is mainly expressed in liver and adipose tissue, as shown by Kersten et al.  that highlighted its upregulation in these tissues during fasting and a PPAR-dependent mRNA regulation, using PPARα/γ wild-type and mutant mice. Also, Kim et al.  identified a novel angiopoietin-like protein mainly expressed in hepatocytes. Finally, Cliff Yoon et al.  proved the regulative relation between PPAR proteins and ANGPTL4, demonstrating that ANGPTL4 is a target of PPARγ in adipose tissue.
ANGPTL4 belongs to a superfamily of secreted proteins structurally related to factors modulating angiogenesis known as angiopoietins (ANG). This protein family includes eight members encoded by eight genes (ANGPTL1-8) identified in humans and mice, except ANGPTL5, that is a human orthologue [25, 27–29]. Only recently, in 2012, a new feeding-induced hepatokine was identified and called RIFL/lipasin/ANGPTL8 (also known as betatrophin) [30–33]. Just in 2015, the HUGO gene nomenclature defined the official name of the protein as ANGPTL8 . Like angiopoietins, all angiopoietin-like proteins (ANGPTLs) exhibit a C-terminal fibrinogen-like globular domain and an N-terminal coiled-coil domain  except for ANGPTL8. Indeed, this last ANGPTL family member is considered an atypical member, since it lacks the main structural features present in all other proteins of the group, such as the fibrinogen-like domain, glycosylation sites, and amino acids requested for formation of disulfide bonds  (Figure 2). Unlike the angiopoietins, ANGPTLs are considered orphan ligands, as they do not bind to either the angiopoietin receptor tyrosine kinase Tie2 or the related protein Tie1 [36–38].
The first four family members (ANGPTL1-4) and ANGPTL6/angiopoietin-related growth factor (AGF) have been shown to modulate angiogenesis. ANGPTLs 3, 4, 5, and 8 and ANGPTL6/AGF seem to be involved also in regulation of other processes such as lipid metabolism and glucose and energy homeostasis [39–46]. Another study showed that ANGPTLs 3 and 4 control lipid metabolism by inhibiting the activity of lipoprotein lipase (LPL) , an enzyme responsible for hydrolysis of triglycerides (TG) contained in lipoproteins, such as chylomicrons and very low-density lipoproteins (VLDL), fatty acids, and cholesterol, whereas ANGPTL6/AGF antagonizes obesity and related metabolic diseases, including insulin resistance, by enhancing systemic energy expenditure .
ANGPTLs show different tissue expression patterns. ANGPTL1 is mostly detected in liver, heart, skeletal muscle, kidney, and vessel-rich endocrine organs (adrenal glands, thyroid, and pituitary gland) but also to a lesser extent in uterus and gastrointestinal tract . ANGPTL2 shows high expression levels in heart, stomach, adipose tissue, skeletal muscle, and uterus , whereas ANGPTL3 is predominantly expressed in liver [50, 51]. ANGPTL4 shows ~30% of sequence homology with ANGPTL3. It is abundantly present in the liver, adipose tissue, and skeletal muscle and, to a lesser extent, in placenta, small intestine, heart, and pituitary gland [52–56]. ANGPTL5 is mainly expressed in adult human heart , whereas ANGPTL6/AGF expression is restricted to liver and plasma . Lastly, ANGPTL7 exhibits high expression levels in the cornea, neural tissues, and trabecular meshwork as well as uterine endometrial cancer and melanoma .
The human gene encoding ANGPTL4 is evolutionarily conserved among species and shares a sequence homology of ~77% with mouse. It is located on chromosome 19p13.3 and consists of seven exons encoding a 406-amino acid glycoprotein. Like other proteins of the ANGPTL family, ANGPTL4 contains a C-terminal fibrinogen-like domain (cANGPTL4) and an N-terminal coiled-coil folding domain (nANGPTL4), in which a highly hydrophobic region that acts as a signal peptide for protein secretion is present. In addition, it exhibits several potential N- and O-glycosylation sites and was found to be N-glycosylated at amino acid position 177 [37, 60]. The same domains of full-length ANGPTL4 (flANGPTL4) protein structure were found in plasma [61, 62]. Higher-order oligomeric structures can be formed by native flANGPTL4 through the formation of intermolecular disulfide bonds. ANGPTL4 contains several conserved cysteine residues that contribute to the formation of variable-sized multimeric structures. The N-terminal oligomerization of ANGPTL4 requires the presence of two cysteine residues (Cys-76 and Cys-80) in the N-terminal portion .
Different studies showed that nANGPTL4 domain is used to modulate lipid metabolism, whereas cANGPTL4 domain may be a modulator of tumorigenesis process . Indeed, ANGPTL4 can exert its function of LPL activity inhibitor thanks to an oligomerization process mediated by the N-terminal region responsible for its assembly into tetrameric or dimeric structures [64–66]. It was hypothesized that LPL blockage is due to 12 highly conserved amino acids that are near the N-terminus of the protein. Indeed, mutations in three polar amino acid residues within this region abolished the ability of ANGPTL4 to inhibit LPL . Experimental evidence showed that several proprotein convertases, including furin, PC5/6 (proprotein convertase 5/6), and PCSK3 (proprotein convertase subtilisin/kexin type 3), catalyze the proteolytic processing of the human flANGPTL4 protein via recognition of a specific amino acid sequence, causing the release of the N-terminal region and monomeric C-terminal portion [66, 67]. ANGPTL4 is cleaved in a tissue-dependent manner and can be secreted into the bloodstream from adipose tissue and liver in native and cleaved, glycosylated, and oligomerized isoforms. In humans, the truncated form is secreted from liver, whereas the full-length form is released from adipose tissue [61, 62]. Furthermore, ANGPTL4 has been shown to bind to heparin sulfate proteoglycans and interact with ECM (extracellular matrix) proteins, by inhibiting endothelial cell adhesion and migration and altering actin cytoskeleton [68–70].
The transcriptional regulation of ANGPTL4 and its resulting expression can be determined by several transcription factors, including PPARα, PPARγ, and HIF-1α. A deeper investigation about transcription activation of ANGPTL4 and all these TFs was done by Inoue et al. . Starting from the evidence that all these factors are important angiogenic molecules, the authors assessed whether there could be a synergic action mechanism of these two different signals in stimulating ANGPTL4 as angiogenesis-related target gene. Indeed, microarray and ChiP-seq analyses showed a cross-enhancement of ANGPTL4 expression dependent on the conformational proximity of two response elements .
Different evidences showed that upregulation of ANGPTL4 expression is strongly linked to fasting in a variety of tissues [72, 73]. Different actors likely mediate the “fasting effect” . Several findings showed that PPARs nuclear receptors induce an increase in ANGPTL4 expression. Glucocorticoids, whose circulating levels are high during fasting, also seem to mediate this event [75–78], and, in addition to fasting, chronic caloric restriction or free fatty acids (also called NEFA) have been shown to increase plasma ANGPTL4 levels . Finally, some studies conducted on human myofibroblasts, using genome-wide transcriptional profiling technology, revealed that human ANGPTL4 expression might be synergistically induced by the functional interactions of TGF-β and PPAR β/δ signaling .
Since ANGPTL4 expression was found mainly in liver and adipose tissue, this molecule was classified, at first, as an adipokine exclusively involved in lipid metabolism. Afterwards, thanks to a large number of studies, this protein has been shown to have a highly multifaceted role, since it is involved in several nonmetabolic and metabolic conditions, both physiological and pathological, including angiogenesis and vascular permeability, cell differentiation, tumorigenesis, glucose homoeostasis, lipid metabolism, energy homeostasis, wound healing, inflammation, and redox regulation .
3. ANGPTL4: A Regulative Role in Glucose and Lipid Metabolism
As previously introduced, among the “pleiotropic” roles of ANGPTL4, greater attention was focused on its involvement in glucose and lipid metabolism regulation . A positive correlation between increased ANGPTL4 and NEFAs levels in plasma of healthy subjects after dietary regimens has been shown. Conversely, the negative energy balance caused by fasting increases the hydrolysis of intracellular TG in adipocytes and other peripheral tissues. This leads to an increase in plasma NEFA levels .
Another recent work by Robciuc et al. showed the involvement of ANGPTL4 in mediating the PPARδ effects on LPL activity in fatty acid (FA) uptake, whereas the effect of PPARδ activation on β-oxidation is independent of ANGPTL4 . Interestingly, the authors investigated also the role played by ANGPTL4 in regulating LPL activity, not only at the level of the surface of capillaries, highlighting the intracellular lipase degradation . Other studies tried to better assess the cellular localization and molecular mechanisms underlying ANGPTL4 role in lipid metabolism, as reported by Dijk et al. . These authors performed ex vivo and in vivo studies on adipocytes and adipose tissue from wild-type and ANGPTL4−/− mice, showing that ANGPTL4 stimulates LPL processing in the endoplasmic reticulum (ER) leading to its intracellular degradation . Another study proposed that LPL regulation by ANGPTL4 occurs at cell surface .
The homeostasis of lipid metabolism is promoted through the intervention of lipases, enzymes that counterbalance LPL activity. Indeed, they hydrolyze stored TG, allowing adipocytes to release FA. Starting from these evidences, an interesting work by Koliwad et al.  showed that ANGPTL4 is a direct glucocorticoid receptor (GR) target and is involved in GR-dependent TG metabolism. Indeed, ANGPTL4-null mice showed lower plasma TG levels and increased ability to gain weight compared to mice overexpressing the gene, suggesting a role of ANGPTL4 in modulating TG homeostasis by regulation of its expression .
Lichtenstein et al.  have well explained the correlation between ANGPTL4 role and inhibition of LPL-mediated plasma TG lipolysis. Thanks to studies derived from transgenic mice, the molecular mechanisms underlying mouse blood TG were deeply revealed. Normally, LPL monomer is associated with the N-terminal domain of ANGPTL4 protein, thus shifting the balance between LPL dimers and monomers towards the latter, causing LPL inhibition and, consequently, determining the alteration of TG clearance from the plasma and FFA uptake decrease into the peripheral tissues .
Another mechanism by which ANGPTL4 inhibits LPL was proposed by Chi et al. These authors showed that ANGPTL4 can bind and inactivate LPL complexed to GPIHBP1. Therefore, the ANGPTL4-mediated LPL inactivation greatly reduces the affinity of LPL for GPIHBP1  (Figure 3).
Considering the discussed role about ANGPTL4 in lipid metabolism, a possible link of this angiopoietin-like protein with obesity was investigated. Different murine models were proposed, highlighting a significant role of this protein in central regulation of energy metabolism . More recently, Robciuc et al. carried out an interesting study on homozygous twins, in which a positive correlation between ANGPTL4 expression levels, adipose tissue hormone-sensitive lipase (LIPE), and CGI-58 gene was shown, supporting the hypothesis of the ANGPTLs’ involvement in promoting lipolysis of adipocytes .
As previously reported, ANGPTL4 is mainly expressed in tissues such as WAT, liver, and skeletal muscle. A recent work by Alex et al.  highlighted protein expression also in human colon adenocarcinoma cells. The authors investigated the role of short-chain fatty acids (SCFA) in HT29 and T48 cell lines and showed an induction of ANGPTL4 synthesis by SCFA through PPARγ receptor activation . Furthermore, long-chain fatty acids have been shown to induce ANGPTL4 production and secretion by PPARδ activation in skeletal muscle cells .
As many scientific papers showed, several proteins, including ANGPTL4, inhibit LPL. A recent study focused the attention on the regulation mechanisms of another lipase, that is, the pancreatic lipase (PL). Interestingly, Mattijssen et al. suggested the involvement of ANGPTL4 also in endogenous inhibition of dietary lipids, through knockout mice experiments  (Figure 4).
However, ANGPTL4 is not the only angiopoietin-like family member involved in maintaining energy metabolism homeostasis. Other two members, such as ANGPTL3 and ANGPTL8, can inhibit LPL activity by affecting plasma TG levels. Indeed, different works showed overexpression of these proteins in mice and humans with increased plasma TG levels. Conversely, mutant mice carrying a loss-of-function of ANGPTLs exhibited low plasma TG levels [32, 92–94], although all three proteins show different tissue expression patterns and are regulated by different stimuli. This has led to the hypothesis that they are active during different metabolic states.
A recent work by Zhang proposed an ANGPTL3-4-8 molecular model to explain TG trafficking specifically in cardiac and skeletal muscles . The model suggests that feeding can induce ANGPTL8, resulting in the activation of the ANGPTL3-8 pathway. This causes LPL inhibition and increase in plasma levels of TG which can be stored in WAT. In this district, decreases in ANGPTL4 concentration allow an increased LPL activity. The opposite scenario is presented during fasting. The impact of the ANGPTLs on plasma lipid levels has led to considering them as therapeutic targets for dyslipidemia .
Decreased plasma levels of this angiopoietin-like protein have been detected also after insulin induction. A recent study focused on the evaluation of the systemic effect of insulin on LPL and its regulative machinery in subjects with a different tolerance degree to insulin and showed a decrease in the adipose tissue ANGPTL4 expression in type 2 diabetes mellitus patients and healthy subjects .
Other evidences concerning the ANGPTL4 role in glucose metabolism regulation were reported in different studies on transgenic mice, where the decrease of blood glucose, improvement of glucose tolerance, and induction of hyperlipidemia and hepatic steatosis have been linked to the protein [44, 98]. More recently, other studies carried out on humans and animal models suggested the involvement of ANGPTL4 in nephrotic syndrome, revealing that ANGPTL4 acts by linking proteinuria and hypertriglyceridemia through negative feedback loops .
4. Role of ANGPTL4 in Cancer
The analysis of the different components of the tumor microenvironment and their cross talk have been the focus of the research of many molecular laboratories, especially since a lot of studies showed the key role played by tumor microenvironment in cancer development and progression. In vivo and in vitro models affirmed the ability of different molecular factors belonging to the tumor microenvironment in regulating cell–cell and cell–matrix communications, cell migration, invasion, and metastatic dissemination, but also in conditioning drastically the efficacy of antitumor therapies [100–102].
Currently, we know well that the malignance grade of a tumor is related to several factors, including genomic instability, heterogeneity (cells types such as fibroblasts, endothelial cells, pericytes, and immune cells), and composition of the microenvironment, which has been shown to change in different cancer types and also among different patients harbouring the same tumor histotype.
To date, the role of ANGPTL4 in cancer progression is not well defined, and there is still some controversy in the literature indicating the need of more studies addressing this interesting topic.
Several studies identified the presence of ANGPTL4 in various solid tumors, such as breast cancer, colorectal cancer, prostate cancer, hepatocarcinoma, and renal cell carcinoma [103–107], suggesting its important role in cancer growth and progression, anoikis resistance, altered redox regulation, angiogenesis, and metastasis [80, 104, 108]. One potential link between ANGPTL4 and tumorigenesis is provided by hypoxia conditions, which represent a prominent feature of tumor microenvironment. Indeed, hypoxia induces overexpression of cyclooxygenase-2 (COX-2) by hypoxia-inducible factor-1 (HIF-1), an oxygen-sensitive transcriptional regulator [109–111], leading to the synthesis of prostanoids, especially prostaglandins PGE2. COX-2 is upregulated in recruited macrophages to trigger activation of other immune cells involved in antitumor response. Increased levels of PGE2 stimulate an intracellular signaling cascade leading to the induction of the ANGPTL4 expression and cANGPTL4 secretion . Although most of studies have not explained the specific role played by ANGPTL4 as entire molecule or generated fragments, currently, several evidences suggested a prevalent activity of cANGPTL4. This fragment seems to be involved in “anoikis resistance,” which is a peculiar feature of metastatic cells acquiring ability to escape programmed cell death. cANGPTL4 interacts with beta-integrins to maintain an elevated ROS rate, inducing a redox-based survival mechanism that involves the activation of the SRC kinase and mitogen-activated protein kinase (MAPK) signaling pathways favoring cancer cell growth and survival .
As regards tumor angiogenesis, there are discordant data about the proangiogenic or antiangiogenic role of ANGPTL4. Several experiments showed that the ANGPTL4 increase by HIF-α stimulates the secretion of multiple proangiogenic factors regardless of vascular endothelial growth factor (VEGF). In this regard, one of the first evidences regards Kaposi’s sarcoma, which is characterized by a deregulated angiogenesis process promoted by the release of proangiogenic molecules. Several in vitro and in vivo studies detected a significant ANGPTL4 upregulation in endothelial cells expressing a deregulated herpesvirus-8- (HHV-8- or KSHV-) encoded G protein-coupled receptor (vGPCR), which is considered a key factor in Kaposi’s sarcoma tumorigenesis. ANGPTL4 inhibition has been associated with a significant decrease of neovascularization and vascular leakage in vitro and vGPCR-mediated tumorigenesis in vivo [114–116]. However, other studies have reported that ANGPTL4 exhibits an antiangiogenic role, inhibiting the proliferation, chemotaxis, and tubule formation of endothelial cells. One of such studies explored the effects of ANGPTL4 on the mouse epidermis through an in vivo neovascularization assay, revealing that ANGPTL4 decreased only VEGF-induced neovascularization, whereas it was not able to influence VEGF-independent neovascularization .
Finally, all these studies suggested that both proangiogenic and antiangiogenic effects of ANGPTL4 are reliable and strongly dependent on the related tumor microenvironment. Several evidences suggested that tumor microenvironment plays a crucial role in multiple steps of tumor development and progression, including drug resistance, immune-escaping, distant metastasis, and angiogenesis . In particular, stromal cells are able to secrete multiple factors, including ANGPTL4, to enhance vasculature permeability in both lung and brain cancers .
Furthermore, as mentioned before, both the secretion and proangiogenic activities of ANGPTL4 are highly dependent on the vGPCR expression by the Kaposi Sarcoma tumor microenvironment. A recent study carried out on patients with uveal melanoma (UM) showed that ANGPTL4 secretion is regulated by HIF-1 and cooperates with VEGF in the angiogenesis promotion, supporting the potential benefit of a combined VEGF-ANGPTL4 inhibition to increase the efficacy of antiangiogenic treatments [119–121]. In addition, a recent work by Xin et al.  showed that HIF-1-induced upregulation of ANGPTL4 may promote vessel permeability in ischemic retinopathies, such as diabetic eye. All these evidences emphasize the need for further investigations about the posttranslational modifications that ANGPTL4 can undergo, to better understand how generated fragments could modulate pro- or anti-angiogenic events.
Some studies suggested that metastatic process seems to be pushed by the activation of human ANGPTL4 via TGF-β. This protein is an essential multifunctional cytokine involved in embryo development and tissue homeostasis but is secreted also in response to hypoxia and/or inflammation. In particular, it has been shown to induce an increase in human ANGPTL4 levels in breast cancer cells, by activating SMAD transcription factors, ultimately favoring the transendothelial migration of tumor cells through disruption of endothelial cell junctions [104, 123]. In hepatocellular carcinoma cells, ANGPTL4 also favors transendothelial migration and metastasis, through upregulation of vascular cell adhesion molecule-1 (VCAM-1) on endothelial cells, and stimulates the VCAM-1/integrin β1 signaling pathway, facilitating the cancer cell transendothelial extravasation to develop distant metastasis . Another study concerning the role of ANGPTL4 in colorectal cancer patients positively correlated ANGPTL4 expression and venous invasion, which is considered the first step of metastatic process. However, the biological mechanism remains elusive . Finally, a study only showed that ANGPTL4 may prevent tumor invasiveness and metastasis through modulation of both endothelial and tumor cell cytoskeleton organization . Taken together, all these data suggest a potential prometastatic role for ANGPTL4, which of course needs to be deeply investigated in further studies, in order to elucidate the biological mechanisms underlying these processes. Since several studies suggested the involvement of ANGPTL4 in vascular permeability, angiogenesis, and inflammatory processes, ANGPTL4-modulating agents, such as PPARs, fatty acids, and specific drugs, could be useful for treatment of associated diseases .
5. ANGPTL4 as Potential Modulator of the Cross Talk between Metabolism and Cancer
Last decade has progressively evidenced two diseases, such as diabetes mellitus and obesity, as contributing factors to cancer onset and development. The first can favor tumor growth by increasing the availability of nutrients (e.g., glucose and FFA) or through alteration of the normal insulin signaling machinery, that causes an increase in blood lipid concentrations [126, 127]. Moreover, FFAs themselves can favor the instauration of oxidative stress through the formation of stress molecules such as reactive oxygen species (ROS), contributing to inflammation and tumor growth [128, 129]. The obesity could also be linked to cancer development through regulative mechanisms linked to adipokines and inflammatory cytokines [130, 131]. Indeed, obesity is characterized by accumulation of visceral adipose tissue that produces high quantities of inflammatory cytokines, mainly leptin, but also IL-1β, TNF-α, IL-8, and IL-6 [74, 132]. In adipocytes, PPARγ activation has been associated with the upregulation of IRS-2 and CAP components of insulin pathway and hence to increased insulin sensitivity . In this complex scenario, we speculated on the potential role played by some “pleiotropic” molecules, such as PPARs isoforms and ANGPTL4, in connecting lipid and glucose metabolism with cancer.
As previously reported, PPARs activation depends on the binding of different ligands. Among the PPAR ligands, there are natural and synthetic compounds, such as fibrates and thiazolidinediones, aimed at contrasting pathological conditions, including the dyslipidemic state (hypertriglyceridemia) and diabetes mellitus [134, 135].
An interesting work by Sethi et al.  showed that LDLs oxidation in endothelial cells causes their activation by PPAR agonists. Other PPAR agonists, such as bezafibrate, have been shown to directly improve insulin sensitivity through the activation of PPARγ isoform .
As previously reported, the different PPAR isoforms are involved in lipid metabolism with different mechanisms of action, depending also on the tissue context in which they are [4, 83, 138–142]. Their deregulation can be evidenced in various tissue contexts. For example, an increase in PPARβ/δ expression was associated with a decreased lipid accumulation during a fat-rich diet in cardiac cells, whereas its overexpression in intestine was linked to colon cancer development . Indeed, Sertznig et al.  showed that colon cancer cell activation depends on the stimulus induced by arachidonic acid, which leads to COX-2 upregulation and overproduction of prostaglandin PGE2. As previously reported, increased levels of PGE2 stimulate an intracellular signaling cascade, leading to the induction of ANGPTL4 expression and cANGPTL4 secretion . Furthermore, macrophage PPARδ induced by Th2 cytokines released by adipocytes has been shown to modulate the polarization of adipose tissue-resident macrophages, causing activation of an anti-inflammatory phenotype and consequently improving insulin sensitivity .
Also PPARγ is involved in lipid metabolism. Similar to PPARβ/δ isoform, it regulates the activity of proteins like LPL [139, 140]. Due to this evidence, probably ANGPTL4, as well as other adipokines, is also a target of PPARγ, acting as a mediator of lipid metabolism. Moreover, PPARγ deregulation was detected not only in peripheral tissues linked to lipid metabolism, but also in inflammation and cancer . Several evidences suggested that PPARγ ligands may be potent inhibitors of angiogenesis mechanisms useful for anticancer therapy [145, 146]. Trombetta et al.  showed that fatty acids, such as docosahexaenoic acid (DHA), activate PPARγ in cancer cells, leading to the inhibition of tumor development. Moreover, studies carried out on WAT, using long-chain monounsaturated fatty acids (LC-MUFAs), revealed a PPARγ overexpression and a decrease of inflammatory markers in diabetes syndrome .
The increasing recognition of the dynamic entity of ANGPTL4 and its multifunctional role in different metabolic and nonmetabolic pathways, the expression network linking PPARs isoform to this angiopoietin-like protein, together with the recent evidences of involvement of PPAR in cancer, led to do some significant speculations on the potential molecular cross talk between these molecules, lipid metabolism, and cancer .
As previously reported, the ANGPTL4 expression depends on different stimuli, such as hypoxia and fasting and, finally, PPARβ/δisoform induction . Interestingly, recent evidences showed that ANGPTL4 expression is activated by PPARβ/δ, not only in adipose tissue but also in response to inflammation during wound healing . Indeed, ANGPTL4 was defined as novel matricellular protein interacting with specific ECM proteins and integrins to facilitate cell migration during this event [54, 69]. This specific function could be linked to the C-terminal domain. Indeed, cANGPTL4 can activate β1 and β5 integrins, through their binding, in order to regulate cell migration via the focal adhesion kinase (FAK)/p21-activated kinase- (PAK-) signaling cascade . Huang et al.  demonstrated that cANGPTL4 may induce vascular disruption through a direct and sequential association with integrin α5β1, VE-cadherin, and claudin-5, favoring metastasis. Other evidences showed that this protein fragment can bind to specific matrix proteins and delay their proteolytic degradation through the intervention of metalloproteinases . Also, the endothelial ANGPTL4 secretion induced by tumor-released semaphorin 4D (SEMA4D) has been shown to modulate vascular permeability . The absence of ANGPTL4 in macrophages has been shown to promote atherosclerosis, inducing foam cell formation and vascular inflammation . Conversely, Georgiadi et al.  showed that ANGPTL4 overexpression reduces uptake of oxidized low-density lipoprotein (oxLDL) by macrophages and inhibits foam cell formation in murine models, consequently by counteracting the atherosclerosis development. More recently, Goh et al.  reported that ANGPTL4 upregulation after inflammatory stimulus determines the regulation of transcription factors involved in epidermal differentiation, such as protein kinase C (PKC) and activator protein-1 (AP-1).
Considering the similarities between the wound healing and cancer microenvironment, it becomes clear how the matricellular role of ANGPTL4 and its up- or downregulation can be translated in the neoplastic cellular context. As evidence of its role in cancer development, several scientific works showed a mRNA deregulation pattern associated with the tumor progression. Indeed, ANGPTL4 mRNA has been found to be upregulated in the perinecrotic areas of different tumor types [154, 155].
A deeper investigation needs to be conducted on the roles played by different functional domains of ANGPTL4. As previously described, together with the full-length protein, nANGPTL4 and cANGPTL4 fragments can also be detected in plasma. Many scientific papers showed a different functional role for each of these protein domains. nANGPTL fragment seems to be mainly responsible for the regulation of lipid metabolism by inhibiting LPL activity, whereas a weaker effect in modulating triglyceride availability seems to be attributable also to flANGPTL4. Conversely, the cANGPTL4 fragment is involved in tumor cell growth, anoikis resistance, angiogenesis inhibition, and wound healing, depending on its interacting molecules  (Figure 5).
Interestingly, the different domains of ANGPTL4 and, consequently, their different roles are correlated to the tissue context in which they act. Obviously, this dependence is linked also to the different partners interacting with the various protein fragments. These evidences taken together led to speculate on the evolutionary benefit of having one protein with many functions correlated to distinct structural domains.
Abundant evidences opened the way to speculate a potential synergic role of PPARs and ANGPTL4 as key players in the cross talk between metabolic syndromes and cancer (Figure 6).
Indeed, as shown, (1) diabetes and obesity are important cancer comorbidity factors; (2) PPARs are involved in lipid and glucose metabolism; (3) PPARγ and PPARβ/δ regulate the expression level of inflammatory cytokines and adipokines, such as leptin and ANGPTL4; (4) the deregulation of PPAR isoforms was detected in different types of cancer; (5) the ANGPTL4 expression depends on the PPAR stimulus. Considering all these points previously discussed, it would be legitimate to hypothesize that ANGPTL4 transcription regulation by PPARs constitutes a gateway between obesity, insulin sensitivity, and cancer.
The authors declare no conflict of interests.
Laura La Paglia and Angela Listì contributed equally to this work.
- I. Issemann and S. Green, “Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators,” Nature, vol. 347, no. 6294, pp. 645–650, 1990.
- J. Berger and D. E. Moller, “The mechanisms of action of PPARs,” Annual Review of Medicine, vol. 53, pp. 409–435, 2002.
- M. Schupp and M. A. Lazar, “Endogenous ligands for nuclear receptors: digging deeper,” Journal of Biological Chemistry, vol. 285, no. 52, pp. 40409–40415, 2010.
- P. Sertznig, M. Seifert, W. Tilgen, and J. Reichrath, “Present concepts and future outlook: function of peroxisome proliferator-activated receptors (PPARs) for pathogenesis, progression, and therapy of cancer,” Journal of Cellular Physiology, vol. 212, no. 1, pp. 1–12, 2007.
- S. R. Pyper, N. Viswakarma, S. Yu, and J. K. Reddy, “PPARalpha: energy combustion, hypolipidemia, inflammation and cancer,” Nuclear receptor signaling, vol. 8, article e002, 2010.
- P. Delerive, C. Furman, E. Teissier, J.-C. Fruchart, P. Duriez, and B. Staels, “Oxidized phospholipids activate PPARα in a phospholipase A2-dependent manner,” FEBS Letters, vol. 471, no. 1, pp. 34–38, 2000.
- G. M. P. G. Attianese and B. Desvergne, “Integrative and systemic approaches for evaluating PPARbeta/delta (PPARD) function,” Nuclear Receptor Signaling, vol. 13, article e001, 2015.
- M. Vázquez-Carrera, “Unraveling the effects of PPARβ/δ on insulin resistance and cardiovascular disease,” Trends in Endocrinology and Metabolism, vol. 27, no. 5, pp. 319–334, 2016.
- K.-D. Wagner and N. Wagner, “Peroxisome proliferator-activated receptor beta/delta (PPARβ/δ) acts as regulator of metabolism linked to multiple cellular functions,” Pharmacology and Therapeutics, vol. 125, no. 3, pp. 423–435, 2010.
- J. G. Neels and P. A. Grimaldi, “Physiological functions of peroxisome proliferator-activated receptor β,” Physiological Reviews, vol. 94, no. 3, pp. 795–858, 2014.
- R. E. Soccio, E. R. Chen, S. R. Rajapurkar et al., “Genetic variation determines PPARγ function and anti-diabetic drug response in vivo,” Cell, vol. 162, no. 1, pp. 33–44, 2015.
- M. Aprile, M. R. Ambrosio, V. D'Esposito et al., “PPARG in human adipogenesis: differential contribution of canonical transcripts and dominant negative isoforms,” PPAR Research, vol. 2014, Article ID 537865, 11 pages, 2014.
- Y.-X. Wang, “PPARs: diverse regulators in energy metabolism and metabolic diseases,” Cell Research, vol. 20, no. 2, pp. 124–137, 2010.
- V. Bermúdez, F. Finol, N. Parra et al., “PPAR-γ agonists and their role in type 2 diabetes mellitus management,” American Journal of Therapeutics, vol. 17, no. 3, pp. 274–283, 2010.
- G. Derosa and P. Maffioli, “Peroxisome proliferator-activated receptor-γ (PPAR-γ) agonists on glycemic control, lipid profile and cardiovascular risk,” Current Molecular Pharmacology, vol. 5, no. 2, pp. 272–281, 2012.
- S. J. Bensinger and P. Tontonoz, “Integration of metabolism and inflammation by lipid-activated nuclear receptors,” Nature, vol. 454, no. 7203, pp. 470–477, 2008.
- M. Terrasi, V. Bazan, S. Caruso et al., “Effects of PPARγ agonists on the expression of leptin and vascular endothelial growth factor in breast cancer cells,” Journal of Cellular Physiology, vol. 228, no. 6, pp. 1368–1374, 2013.
- B. P. Kota, T. H.-W. Huang, and B. D. Roufogalis, “An overview on biological mechanisms of PPARs,” Pharmacological Research, vol. 51, no. 2, pp. 85–94, 2005.
- T. Mello, S. Polvani, and A. Galli, “Peroxisome proliferator-activated receptor and retinoic X receptor in alcoholic liver disease,” PPAR Research, vol. 2009, Article ID 748174, 11 pages, 2009.
- S. A. Kliewer, K. Umesono, D. J. Noonan, R. A. Heyman, and R. M. Evans, “Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors,” Nature, vol. 358, no. 6389, pp. 771–774, 1992.
- N. Viswakarma, Y. Jia, L. Bai et al., “Coactivators in PPAR-regulated gene expression,” PPAR Research, vol. 2010, Article ID 250126, 21 pages, 2010.
- V. Martínez-Redondo, A. T. Pettersson, and J. L. Ruas, “The hitchhiker's guide to PGC-1α isoform structure and biological functions,” Diabetologia, vol. 58, no. 9, pp. 1969–1977, 2015.
- F. A. Monsalve, R. D. Pyarasani, F. Delgado-Lopez, and R. Moore-Carrasco, “Peroxisome proliferator-activated receptor targets for the treatment of metabolic diseases,” Mediators of Inflammation, vol. 2013, Article ID 549627, 18 pages, 2013.
- S. Kersten, S. Mandard, N. S. Tan et al., “Characterization of the fasting-induced adipose factor FIAF, a novel peroxisome proliferator-activated receptor target gene,” Journal of Biological Chemistry, vol. 275, no. 37, pp. 28488–28493, 2000.
- I. Kim, H.-G. Kim, H. Kim et al., “Hepatic expression, synthesis and secretion of a novel fibrinogen/angiopoietin-related protein that prevents endothelial-cell apoptosis,” Biochemical Journal, vol. 346, no. 3, pp. 603–610, 2000.
- J. Cliff Yoon, T. W. Chickering, E. D. Rosen et al., “Peroxisome proliferator-activated receptor γ target gene encoding a novel angiopoietin-related protein associated with adipose differentiation,” Molecular and Cellular Biology, vol. 20, no. 14, pp. 5343–5349, 2000.
- Y. Ito, Y. Oike, K. Yasunaga et al., “Inhibition of angiogenesis and vascular leakiness by angiopoietin-related protein 4,” Cancer Research, vol. 63, no. 20, pp. 6651–6657, 2003.
- I. Kim, H. J. Kwak, J. E. Ahn et al., “Molecular cloning and characterization of a novel angiopoietin family protein, angiopoietin-3,” FEBS Letters, vol. 443, no. 3, pp. 353–356, 1999.
- G. Santulli, “Angiopoietin-like proteins: a comprehensive look,” Frontiers in Endocrinology, vol. 5, article 4, 2014.
- G. Ren, J. Y. Kim, and C. M. Smas, “Identification of RIFL, a novel adipocyte-enriched insulin target gene with a role in lipid metabolism,” American Journal of Physiology—Endocrinology and Metabolism, vol. 303, no. 3, pp. E334–E351, 2012.
- R. Zhang, “Lipasin, a novel nutritionally-regulated liver-enriched factor that regulates serum triglyceride levels,” Biochemical and Biophysical Research Communications, vol. 424, no. 4, pp. 786–792, 2012.
- F. Quagliarini, Y. Wang, J. Kozlitina et al., “Atypical angiopoietin-like protein that regulates ANGPTL3,” Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 48, pp. 19751–19756, 2012.
- P. Yi, J. S. Park, and D. A. Melton, “Betatrophin: a hormone that controls pancreatic beta cell proliferation,” Cell, vol. 153, no. 4, pp. 747–758, 2013.
- K. A. Gray, B. Yates, R. L. Seal, M. W. Wright, and E. A. Bruford, “Genenames.org: the HGNC resources in 2015,” Nucleic Acids Research, vol. 43, no. 1, pp. D1079–D1085, 2015.
- Y. Oike, K. Yasunaga, and T. Suda, “Angiopoietin-related/angiopoietin-like proteins regulate angiogenesis,” International Journal of Hematology, vol. 80, no. 1, pp. 21–28, 2004.
- T. Hato, M. Tabata, and Y. Oike, “The role of angiopoietin-like proteins in angiogenesis and metabolism,” Trends in Cardiovascular Medicine, vol. 18, no. 1, pp. 6–14, 2008.
- I. Kim, S.-O. Moon, K. N. Koh et al., “Molecular cloning, expression, and characterization of angiopoietin- related protein. Angiopoietin-related protein induces endothelial cell sprouting,” Journal of Biological Chemistry, vol. 274, no. 37, pp. 26523–26528, 1999.
- Y. Katoh and M. Katoh, “Comparative integromics on Angiopoietin family members,” International Journal of Molecular Medicine, vol. 17, no. 6, pp. 1145–1149, 2006.
- Y. Oike, K. Yasunaga, Y. Ito et al., “Angiopoietin-related growth factor (AGF) promotes epidermal proliferation, remodeling, and regeneration,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 16, pp. 9494–9499, 2003.
- Y. Oike, Y. Ito, H. Maekawa et al., “Angiopoietin-related growth factor (AGF) promotes angiogenesis,” Blood, vol. 103, no. 10, pp. 3760–3765, 2004.
- M. Ono, T. Shimizugawa, M. Shimamura et al., “Protein region important for regulation of lipid metabolism in angiopoietin-like 3 (ANGPTL3): ANGPTL3 is cleaved and activated in vivo,” Journal of Biological Chemistry, vol. 278, no. 43, pp. 41804–41809, 2003.
- M. Shimamura, M. Matsuda, H. Yasumo et al., “Angiopoietin-like protein3 regulates plasma HDL cholesterol through suppression of endothelial lipase,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 27, no. 2, pp. 366–372, 2007.
- Y. Wang, K. S. L. Lam, J. B. B. Lam et al., “Overexpression of angiopoietin-like protein 4 alters mitochondria activities and modulates methionine metabolic cycle in the liver tissues of db/db diabetic mice,” Molecular Endocrinology, vol. 21, no. 4, pp. 972–986, 2007.
- A. Xu, M. C. Lam, K. W. Chan et al., “Angiopoietin-like protein 4 decreases blood glucose and improves glucose tolerance but induces hyperlipidemia and hepatic steatosis in mice,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 17, pp. 6086–6091, 2005.
- Y. Oike, M. Akao, K. Yasunaga et al., “Angiopoietin-related growth factor antagonizes obesity and insulin resistance,” Nature Medicine, vol. 11, no. 4, pp. 400–408, 2005.
- H. Ge, J.-Y. Cha, H. Gopal et al., “Differential regulation and properties of angiopoietin-like proteins 3 and 4,” Journal of Lipid Research, vol. 46, no. 7, pp. 1484–1490, 2005.
- E.-C. Lee, U. Desai, G. Gololobov et al., “Identification of a new functional domain in angiopoietin-like 3 (ANGPTL3) and angiopoietin-like 4 (ANGPTL4) involved in binding and inhibition of lipoprotein lipase (LPL),” Journal of Biological Chemistry, vol. 284, no. 20, pp. 13735–13745, 2009.
- D.-M. Lai, Y.-K. Tu, Y.-H. Hsieh et al., “Angiopoietin-like protein 1 expression is related to intermuscular connective tissue and cartilage development,” Developmental Dynamics, vol. 236, no. 9, pp. 2643–2652, 2007.
- N. Thorin-Trescases and E. Thorin, “Angiopoietin-like-2: a multifaceted protein with physiological and pathophysiological properties,” Expert Reviews in Molecular Medicine, vol. 16, article e17, 2014.
- M. Arca, I. Minicocci, and M. Maranghi, “The angiopoietin-like protein 3: a hepatokine with expanding role in metabolism,” Current Opinion in Lipidology, vol. 24, no. 4, pp. 313–320, 2013.
- G. Camenisch, M. T. Pisabarro, D. Sherman et al., “ANGPTL3 stimulates endothelial cell adhesion and migration via integrin αvβ3 and induces blood vessel formation in vivo,” Journal of Biological Chemistry, vol. 277, no. 19, pp. 17281–17290, 2002.
- W. Dijk and S. Kersten, “Regulation of lipoprotein lipase by Angptl4,” Trends in Endocrinology and Metabolism, vol. 25, no. 3, pp. 146–155, 2014.
- Y. Oike, M. Akao, Y. Kubota, and T. Suda, “Angiopoietin-like proteins: potential new targets for metabolic syndrome therapy,” Trends in Molecular Medicine, vol. 11, no. 10, pp. 473–479, 2005.
- M. J. Tan, Z. Teo, M. K. Sng, P. Zhu, and N. S. Tan, “Emerging roles of angiopoietin-like 4 in human cancer,” Molecular Cancer Research, vol. 10, no. 6, pp. 677–688, 2012.
- Y.-H. Tseng, Y.-H. Yeh, W.-J. Chen, and K.-H. Lin, “Emerging regulation and function of betatrophin,” International Journal of Molecular Sciences, vol. 15, no. 12, pp. 23640–23657, 2014.
- S. Kersten, L. Lichtenstein, E. Steenbergen et al., “Caloric restriction and exercise increase plasma ANGPTL4 levels in humans via elevated free fatty acids,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 29, no. 6, pp. 969–974, 2009.
- L. Zeng, J. Dai, K. Ying et al., “Identification of a novel human angiopoietin-like gene expressed mainly in heart,” Journal of Human Genetics, vol. 48, no. 3, pp. 159–162, 2003.
- T. Kadomatsu, M. Tabata, and Y. Oike, “Angiopoietin-like proteins: emerging targets for treatment of obesity and related metabolic diseases,” FEBS Journal, vol. 278, no. 4, pp. 559–564, 2011.
- T. Toyono, T. Usui, S. Yokoo et al., “Angiopoietin-like 7 is an anti-angiogenic protein required to prevent vascularization of the cornea,” PLoS ONE, vol. 10, no. 1, Article ID e0116838., 2015.
- C. Grootaert, T. Van De Wiele, W. Verstraete, M. Bracke, and B. Vanhoecke, “Angiopoietin-like protein 4: health effects, modulating agents and structure-function relationships,” Expert Review of Proteomics, vol. 9, no. 2, pp. 181–199, 2012.
- S. Mandard, F. Zandbergen, N. S. Tan et al., “The direct peroxisome proliferator-activated receptor target fasting-induced adipose factor (FIAF/PGAR/ANGPTL4) is present in blood plasma as a truncated protein that is increased by fenofibrate treatment,” The Journal of Biological Chemistry, vol. 279, no. 33, pp. 34411–34420, 2004.
- H. Ge, G. Yang, X. Yu, T. Pourbahrami, and C. Li, “Oligomerization state-dependent hyperlipidemic effect of angiopoietin-like protein 4,” Journal of Lipid Research, vol. 45, no. 11, pp. 2071–2079, 2004.
- W. Yin, S. Romeo, S. Chang, N. V. Grishin, H. H. Hobbs, and J. C. Cohen, “Genetic variation in ANGPTL4 provides insights into protein processing and function,” Journal of Biological Chemistry, vol. 284, no. 19, pp. 13213–13222, 2009.
- V. Sukonina, A. Lookene, T. Olivecrona, and G. Olivecrona, “Angiopoietin-like protein 4 converts lipoprotein lipase to inactive monomers and modulates lipase activity in adipose tissue,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 46, pp. 17450–17455, 2006.
- H. Ge, G. Yang, L. Huang, D. L. Motola, T. Pourbahrami, and C. Li, “Oligomerization and regulated proteolytic processing of angiopoietin-like protein 4,” Journal of Biological Chemistry, vol. 279, no. 3, pp. 2038–2045, 2004.
- M.-H. Yau, Y. Wang, K. S. L. Lam, J. Zhang, D. Wu, and A. Xu, “A highly conserved motif within the NH2-terminal coiled-coil domain of angiopoietin-like protein 4 confers its inhibitory effects on lipoprotein lipase by disrupting the enzyme dimerization,” Journal of Biological Chemistry, vol. 284, no. 18, pp. 11942–11952, 2009.
- X. Lei, F. Shi, D. Basu et al., “Proteolytic processing of angiopoietin-like protein 4 by proprotein convertases modulates its inhibitory effects on lipoprotein lipase activity,” The Journal of Biological Chemistry, vol. 286, no. 18, pp. 15747–15756, 2011.
- A. Cazes, A. Galaup, C. Chomel et al., “Extracellular matrix-bound angiopoietin-like 4 inhibits endothelial cell adhesion, migration, and sprouting and alters actin cytoskeleton,” Circulation Research, vol. 99, no. 11, pp. 1207–1215, 2006.
- Y. Y. Goh, M. Pal, H. C. Chong et al., “Angiopoietin-like 4 interacts with integrins β1 and β5 to modulate keratinocyte migration,” American Journal of Pathology, vol. 177, no. 6, pp. 2791–2803, 2010.
- Y. Y. Goh, M. Pal, H. C. Chong et al., “Angiopoietin-like 4 interacts with matrix proteins to modulate wound healing,” Journal of Biological Chemistry, vol. 285, no. 43, pp. 32999–33009, 2010.
- T. Inoue, T. Kohro, T. Tanaka et al., “Cross-enhancement of ANGPTL4 transcription by HIF1 alpha and PPAR beta/delta is the result of the conformational proximity of two response elements,” Genome Biology, vol. 15, no. 4, article no. R63, 2014.
- G. Wiesner, B. A. Morash, E. Ur, and M. Wilkinson, “Food restriction regulates adipose-specific cytokines in pituitary gland but not in hypothalamus,” Journal of Endocrinology, vol. 180, no. 3, pp. R1–R6, 2004.
- L. Lichtenstein, J. F. P. Berbée, S. J. van Dijk et al., “Angptl4 upregulates cholesterol synthesis in liver via inhibition of LPL- and HL-dependent hepatic cholesterol uptake,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 27, no. 11, pp. 2420–2427, 2007.
- A. Cangemi, D. Fanale, G. Rinaldi et al., “Dietary restriction: could it be considered as speed bump on tumor progression road?” Tumor Biology, vol. 37, no. 6, pp. 7109–7118, 2016.
- P. González-Muniesa, C. De Oliveira, F. Pérez De Heredia, M. P. Thompson, and P. Trayhurn, “Fatty acids and hypoxia stimulate the expression and secretion of the adipokine ANGPTL4 (angiopoietin-like protein 4/ fasting-induced adipose factor) by human adipocytes,” Journal of Nutrigenetics and Nutrigenomics, vol. 4, no. 3, pp. 146–153, 2011.
- T. Baranowski, S. Kralisch, A. Bachmann et al., “Serum levels of the adipokine fasting-induced adipose factor/angiopoietin-like protein 4 depend on renal function,” Hormone and Metabolic Research, vol. 43, no. 2, pp. 117–120, 2011.
- E. M. van Leeuwen, A. Sabo, J. C. Bis et al., “Meta-analysis of 49 549 individuals imputed with the 1000 Genomes Project reveals an exonic damaging variant in ANGPTL4 determining fasting TG levels,” Journal of Medical Genetics, vol. 53, no. 7, pp. 441–449, 2016.
- S. K. Koliwad, T. Kuo, L. E. Shipp et al., “Angiopoietin-like 4 (ANGPTL4, fasting-induced adipose factor) is a direct glucocorticoid receptor target and participates in glucocorticoid-regulated triglyceride metabolism,” Journal of Biological Chemistry, vol. 284, no. 38, pp. 25593–25601, 2009.
- K. Kaddatz, T. Adhikary, F. Finkernagel, W. Meissner, S. Müller-Brüsselbach, and R. Müller, “Transcriptional profiling identifies functional interactions of TGFβ and PPARβ/δ signaling: synergistic induction of ANGPTL4 transcription,” Journal of Biological Chemistry, vol. 285, no. 38, pp. 29469–29479, 2010.
- P. Zhu, Y. Y. Goh, H. F. A. Chin, S. Kersten, and N. S. Tan, “Angiopoietin-like 4: a decade of research,” Bioscience Reports, vol. 32, no. 3, pp. 211–219, 2012.
- S. Mandard, F. Zandbergen, E. van Straten et al., “The fasting-induced adipose factor/angiopoietin-like protein 4 is physically associated with lipoproteins and governs plasma lipid levels and adiposity,” The Journal of Biological Chemistry, vol. 281, no. 2, pp. 934–944, 2006.
- J. T. Jonker, J. W. A. Smit, S. Hammer et al., “Dietary modulation of plasma angiopoietin-like protein 4 concentrations in healthy volunteers and in patients with type 2 diabetes,” The American Journal of Clinical Nutrition, vol. 97, no. 2, pp. 255–260, 2013.
- M. R. Robciuc, P. Skrobuk, A. Anisimov et al., “Angiopoietin-like 4 mediates PPAR delta effect on lipoprotein lipase-dependent fatty acid uptake but not on beta-oxidation in myotubes,” PLoS ONE, vol. 7, no. 10, Article ID e46212, 2012.
- W. Dijk, A. P. Beigneux, M. Larsson, A. Bensadoun, S. G. Young, and S. Kersten, “Angiopoietin-like 4 promotes intracellular degradation of lipoprotein lipase in adipocytes,” Journal of Lipid Research, vol. 57, no. 9, pp. 1670–1683, 2016.
- E. Makoveichuk, E. Vorrsjö, T. Olivecrona, and G. Olivecrona, “Inactivation of lipoprotein lipase in 3T3-L1 adipocytes by angiopoietin-like protein 4 requires that both proteins have reached the cell surface,” Biochemical and Biophysical Research Communications, vol. 441, no. 4, pp. 941–946, 2013.
- X. Chi, S. K. Shetty, H. W. Shows, A. J. Hjelmaas, E. K. Malcolm, and B. S. J. Davies, “Angiopoietin-like 4 modifies the interactions between lipoprotein lipase and its endothelial cell transporter GPIHBP1,” Journal of Biological Chemistry, vol. 290, no. 19, pp. 11865–11877, 2015.
- H.-K. Kim, B.-S. Youn, M.-S. Shin et al., “Hypothalamic Angptl4/Fiaf is a novel regulator of food intake and body weight,” Diabetes, vol. 59, no. 11, pp. 2772–2780, 2010.
- M. R. Robciuc, J. Naukkarinen, A. Ortega-Alonso et al., “Serum angiopoietin-like 4 protein levels and expression in adipose tissue are inversely correlated with obesity in monozygotic twins,” Journal of Lipid Research, vol. 52, no. 8, pp. 1575–1582, 2011.
- S. Alex, K. Lange, T. Amolo et al., “Short-chain fatty acids stimulate angiopoietin-like 4 synthesis in human colon adenocarcinoma cells by activating peroxisome proliferator-activated receptor γ,” Molecular and Cellular Biology, vol. 33, no. 7, pp. 1303–1316, 2013.
- H. Staiger, C. Haas, J. Machann et al., “Muscle-derived angiopoietin-like protein 4 is induced by fatty acids via peroxisome proliferator-activated receptor (PPAR)-δ and is of metabolic relevance in humans,” Diabetes, vol. 58, no. 3, pp. 579–589, 2009.
- F. Mattijssen, S. Alex, H. J. Swarts, A. K. Groen, E. M. van Schothorst, and S. Kersten, “Angptl4 serves as an endogenous inhibitor of intestinal lipid digestion,” Molecular Metabolism, vol. 3, no. 2, pp. 135–144, 2014.
- R. Koishi, Y. Ando, M. Ono et al., “Angptl3 regulates lipid metabolism in mice,” Nature Genetics, vol. 30, no. 2, pp. 151–157, 2002.
- Y. Wang, F. Quagliarini, V. Gusarova et al., “Mice lacking ANGPTL8 (Betatrophin) manifest disrupted triglyceride metabolism without impaired glucose homeostasis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 110, no. 40, pp. 16109–16114, 2013.
- R. Zhang and A. B. Abou-Samra, “Emerging roles of Lipasin as a critical lipid regulator,” Biochemical and Biophysical Research Communications, vol. 432, no. 3, pp. 401–405, 2013.
- R. Zhang, “The ANGPTL3-4-8 model, a molecular mechanism for triglyceride trafficking,” Open Biology, vol. 6, no. 4, Article ID 150272, 2016.
- W. Dijk and S. Kersten, “Regulation of lipid metabolism by angiopoietin-like proteins,” Current Opinion in Lipidology, vol. 27, no. 3, pp. 249–256, 2016.
- T. Ruge, V. Sukonina, O. Kroupa et al., “Effects of hyperinsulinemia on lipoprotein lipase, angiopoietin-like protein 4, and glycosylphosphatidylinositol-anchored high-density lipoprotein binding protein 1 in subjects with and without type 2 diabetes mellitus,” Metabolism: Clinical and Experimental, vol. 61, no. 5, pp. 652–660, 2012.
- Y. Wang, L. Liu, L. Wei et al., “Angiopoietin-like protein 4 improves glucose tolerance and insulin resistance but induces liver steatosis in high-fat-diet mice,” Molecular Medicine Reports, vol. 14, no. 4, pp. 3293–3300, 2016.
- L. C. Clement, C. Macé, C. Avila-Casado, J. A. Joles, S. Kersten, and S. S. Chugh, “Circulating angiopoietin-like 4 links proteinuria with hypertriglyceridemia in nephrotic syndrome,” Nature Medicine, vol. 20, no. 1, pp. 37–46, 2014.
- R. Lu, S. Wu, Y. G. Zhang et al., “Salmonella protein AvrA activates the STAT3 signaling pathway in colon cancer,” Neoplasia, vol. 18, no. 5, pp. 307–316, 2016.
- S. Sivaprakasam, A. Gurav, A. V. Paschall et al., “An essential role of Ffar2 (Gpr43) in dietary fibre-mediated promotion of healthy composition of gut microbiota and suppression of intestinal carcinogenesis,” Oncogenesis, vol. 5, no. 6, article e238, 2016.
- Y. Miki, Y. Kidoguchi, M. Sato et al., “Dual roles of group IID phospholipase A2 in inflammation and cancer,” Journal of Biological Chemistry, vol. 291, no. 30, pp. 15588–15601, 2016.
- T. Nakayama, H. Hirakawa, K. Shibata, K. Abe, T. Nagayasu, and T. Taguchi, “Expression of angiopoietin-like 4 in human gastric cancer: ANGPTL4 promotes venous invasion,” Oncology Reports, vol. 24, no. 3, pp. 599–606, 2010.
- T. Nakayama, H. Hirakawa, K. Shibata et al., “Expression of angiopoietin-like 4 (ANGPTL4) in human colorectal cancer: ANGPTL4 promotes venous invasion and distant metastasis,” Oncology Reports, vol. 25, no. 4, pp. 929–935, 2011.
- K. Shibata, T. Nakayama, H. Hirakawa, S. Hidaka, and T. Nagayasu, “Clinicopathological significance of angiopoietin-like protein 4 expression in oesophageal squamous cell carcinoma,” Journal of Clinical Pathology, vol. 63, no. 12, pp. 1054–1058, 2010.
- Z. Wang, B. Han, Z. Zhang, J. Pan, and H. Xia, “Expression of angiopoietin-like 4 and tenascin C but not cathepsin C mRNA predicts prognosis of oral tongue squamous cell carcinoma,” Biomarkers, vol. 15, no. 1, pp. 39–46, 2010.
- S. Le Jan, C. Amy, A. Cazes et al., “Angiopoietin-like 4 is a proangiogenic factor produced during ischemia and in conventional renal cell carcinoma,” The American Journal of Pathology, vol. 162, no. 5, pp. 1521–1528, 2003.
- X.-F. Huang, J. Han, X.-T. Hu, and C. He, “Mechanisms involved in biological behavior changes associated with Angptl4 expression in colon cancer cell lines,” Oncology Reports, vol. 27, no. 5, pp. 1541–1547, 2012.
- H. Shengwei, X. Wenguang, W. Zhiyong et al., “Crosstalk between the HIF-1 and toll-like receptor/nuclear factor-κB pathways in the oral squamous cell carcinoma microenvironment,” Oncotarget, vol. 7, no. 25, pp. 37773–37789, 2016.
- D. Fanale, V. Bazan, S. Caruso et al., “Hypoxia and human genome stability: downregulation of BRCA2 expression in breast cancer cell lines,” BioMed Research International, vol. 2013, Article ID 746858, 8 pages, 2013.
- D. Fanale, V. Bazan, L. R. Corsini et al., “HIF-1 is involved in the negative regulation of AURKA expression in breast cancer cell lines under hypoxic conditions,” Breast Cancer Research and Treatment, vol. 140, no. 3, pp. 505–517, 2013.
- S.-H. Kim, Y.-Y. Park, S.-W. Kim, J.-S. Lee, D. Wang, and R. N. DuBois, “ANGPTL4 induction by prostaglandin E2 under hypoxic conditions promotes colorectal cancer progression,” Cancer Research, vol. 71, no. 22, pp. 7010–7020, 2011.
- P. Zhu, M. J. Tan, R.-L. Huang et al., “Angiopoietin-like 4 protein elevates the prosurvival intracellular O2−:H2O2 ratio and confers anoikis resistance to tumors,” Cancer Cell, vol. 19, no. 3, pp. 401–415, 2011.
- J. Hu, B. C. Jham, T. Ma et al., “Angiopoietin-like 4: a novel molecular hallmark in oral Kaposi's sarcoma,” Oral Oncology, vol. 47, no. 5, pp. 371–375, 2011.
- T. Ma, B. C. Jham, J. Hu et al., “Viral G protein-coupled receptor up-regulates Angiopoietin-like 4 promoting angiogenesis and vascular permeability in Kaposi's sarcoma,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 32, pp. 14363–14368, 2010.
- A. Galaup, A. Cazes, S. Le Jan et al., “Angiopoietin-like 4 prevents metastasis through inhibition of vascular permeability and tumor cell motility and invasiveness,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 49, pp. 18721–18726, 2006.
- F. Chen, X. Zhuang, L. Lin et al., “New horizons in tumor microenvironment biology: challenges and opportunities,” BMC Medicine, vol. 13, article 45, 2015.
- L. Wan, K. Pantel, and Y. Kang, “Tumor metastasis: moving new biological insights into the clinic,” Nature Medicine, vol. 19, no. 11, pp. 1450–1464, 2013.
- N. S. Vasudev and A. R. Reynolds, “Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions,” Angiogenesis, vol. 17, no. 3, pp. 471–494, 2014.
- K. Hu, S. Babapoor-Farrokhran, M. Rodrigues et al., “Hypoxia-inducible factor 1 upregulation of both VEGF and ANGPTL4 is required to promote the angiogenic phenotype in uveal melanoma,” Oncotarget, vol. 7, no. 7, pp. 7816–7828, 2016.
- S. Babapoor-Farrokhran, K. Jee, B. Puchner et al., “Angiopoietin-like 4 is a potent angiogenic factor and a novel therapeutic target for patients with proliferative diabetic retinopathy,” Proceedings of the National Academy of Sciences of the United States of America, vol. 112, no. 23, pp. E3030–E3039, 2015.
- X. Xin, M. Rodrigues, M. Umapathi et al., “Hypoxic retinal Müller cells promote vascular permeability by HIF-1-dependent up-regulation of angiopoietin-like 4,” Proceedings of the National Academy of Sciences of the United States of America, vol. 110, no. 36, pp. E3425–E3434, 2013.
- D. Padua, X. H.-F. Zhang, Q. Wang et al., “TGFβ primes breast tumors for lung metastasis seeding through angiopoietin-like 4,” Cell, vol. 133, no. 1, pp. 66–77, 2008.
- H. Li, C. Ge, F. Zhao et al., “Hypoxia-inducible factor 1 alpha–activated angiopoietin-like protein 4 contributes to tumor metastasis via vascular cell adhesion molecule-1/integrin β1 signaling in human hepatocellular carcinoma,” Hepatology, vol. 54, no. 3, pp. 910–919, 2011.
- L. Guo, S.-Y. Li, F.-Y. Ji et al., “Role of Angptl4 in vascular permeability and inflammation,” Inflammation Research, vol. 63, no. 1, pp. 13–22, 2014.
- T. Salvatore, R. Marfella, M. R. Rizzo, and F. C. Sasso, “Pancreatic cancer and diabetes: a two-way relationship in the perspective of diabetologist,” International Journal of Surgery, vol. 21, no. 1, pp. S72–S77, 2015.
- M. Trajkovic-Arsic, E. Kalideris, and J. T. Siveke, “The role of insulin and IGF system in pancreatic cancer,” Journal of Molecular Endocrinology, vol. 50, no. 3, pp. R67–R74, 2013.
- C. M. Sousa and A. C. Kimmelman, “The complex landscape of pancreatic cancer metabolism,” Carcinogenesis, vol. 35, no. 7, pp. 1441–1450, 2014.
- L. K. Mamedova, K. Yuan, A. N. Laudick, S. D. Fleming, D. G. Mashek, and B. J. Bradford, “Toll-like receptor 4 signaling is required for induction of gluconeogenic gene expression by palmitate in human hepatic carcinoma cells,” Journal of Nutritional Biochemistry, vol. 24, no. 8, pp. 1499–1507, 2013.
- M. J. Khandekar, P. Cohen, and B. M. Spiegelman, “Molecular mechanisms of cancer development in obesity,” Nature Reviews Cancer, vol. 11, no. 12, pp. 886–895, 2011.
- N. A. Berger, “Obesity and cancer pathogenesis,” Annals of the New York Academy of Sciences, vol. 1311, no. 1, pp. 57–76, 2014.
- K. E. O'Sullivan, J. V. Reynolds, C. O'Hanlon, J. N. O'Sullivan, and J. Lysaght, “Could signal transducer and activator of transcription 3 be a therapeutic target in obesity-related gastrointestinal malignancy?” Journal of Gastrointestinal Cancer, vol. 45, no. 1, pp. 1–11, 2014.
- S. Polvani, M. Tarocchi, S. Tempesti, L. Bencini, and A. Galli, “Peroxisome proliferator activated receptors at the crossroad of obesity, diabetes, and pancreatic cancer,” World Journal of Gastroenterology, vol. 22, no. 8, pp. 2441–2459, 2016.
- A. Taniguchi, M. Fukushima, M. Sakai et al., “Effects of bezafibrate on insulin sensitivity and insulin secretion in non-obese Japanese type 2 diabetic patients,” Metabolism, vol. 50, no. 4, pp. 477–480, 2001.
- T. Nakamura, C. Ushiyama, N. Shimada, K. Hayashi, I. Ebihara, and H. Koide, “Comparative effects of pioglitazone, glibenclamide, and voglibose on urinary endothelin-1 and albumin excretion in diabetes patients,” Journal of Diabetes and Its Complications, vol. 14, no. 5, pp. 250–254, 2000.
- S. Sethi, O. Ziouzenkova, H. Ni, D. D. Wagner, J. Plutzky, and T. N. Mayadas, “Oxidized omega-3 fatty acids in fish oil inhibit leukocyte-endothelial interactions through activation of PPARα,” Blood, vol. 100, no. 4, pp. 1340–1346, 2002.
- B. Grygiel-Górniak, “Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications—a review,” Nutrition Journal, vol. 13, article 17, 2014.
- Y.-X. Wang, C.-H. Lee, S. Tiep et al., “Peroxisome-proliferator-activated receptor δ activates fat metabolism to prevent obesity,” Cell, vol. 113, no. 2, pp. 159–170, 2003.
- M. Lehrke and M. A. Lazar, “The many faces of PPARγ,” Cell, vol. 123, no. 6, pp. 993–999, 2005.
- G. Medina-Gomez, S. L. Gray, L. Yetukuri et al., “PPAR gamma 2 prevents lipotoxicity by controlling adipose tissue expandability and peripheral lipid metabolism,” PLOS genetics, vol. 3, no. 4, article e64, 2007.
- M. S. Rao, K. Papreddy, S. Musunuri, and A. Okonkwo, “Prevention/reversal of choline deficiency-induced steatohepatitis by a peroxisome proliferator-activated receptor α ligand in rats,” In Vivo, vol. 16, no. 2, pp. 145–152, 2002.
- L. Michalik, B. Desvergne, and W. Wahli, “Peroxisome-proliferator-activated receptors and cancers: complex stories,” Nature Reviews Cancer, vol. 4, no. 1, pp. 61–70, 2004.
- K. Kang, S. M. Reilly, V. Karabacak et al., “Adipocyte-derived Th2 cytokines and myeloid PPARδ regulate macrophage polarization and insulin sensitivity,” Cell Metabolism, vol. 7, no. 6, pp. 485–495, 2008.
- S. Mandard and D. Patsouris, “Nuclear control of the inflammatory response in mammals by peroxisome proliferator-activated receptors,” PPAR Research, vol. 2013, Article ID 613864, 23 pages, 2013.
- X. Xin, S. Yang, J. Kowalski, and M. E. Gerritsen, “Peroxisome proliferator-activated receptor γ ligands are potent inhibitors of angiogenesis in vitro and in vivo,” The Journal of Biological Chemistry, vol. 274, no. 13, pp. 9116–9121, 1999.
- A. Margeli, G. Kouraklis, and S. Theocharis, “Peroxisome proliferator activated receptor-γ (PPAR-γ) ligands and angiogenesis,” Angiogenesis, vol. 6, no. 3, pp. 165–169, 2003.
- A. Trombetta, M. Maggiora, G. Martinasso, P. Cotogni, R. A. Canuto, and G. Muzio, “Arachidonic and docosahexaenoic acids reduce the growth of A549 human lung-tumor cells increasing lipid peroxidation and PPARs,” Chemico-Biological Interactions, vol. 165, no. 3, pp. 239–250, 2007.
- Z.-H. Yang, H. Miyahara, Y. Iwasaki, J. Takeo, and M. Katayama, “Dietary supplementation with long-chain monounsaturated fatty acids attenuates obesity-related metabolic dysfunction and increases expression of PPAR gamma in adipose tissue in type 2 diabetic KK-Ay mice,” Nutrition and Metabolism, vol. 10, no. 1, article 16, 2013.
- E. Mueller, P. Sarraf, P. Tontonoz et al., “Terminal differentiation of human breast cancer through PPARγ,” Molecular Cell, vol. 1, no. 3, pp. 465–470, 1998.
- R.-L. Huang, Z. Teo, H. C. Chong et al., “ANGPTL4 modulates vascular junction integrity by integrin signaling and disruption of intercellular VE-cadherin and claudin-5 clusters,” Blood, vol. 118, no. 14, pp. 3990–4002, 2011.
- H. Zhou, Y.-H. Yang, and J. R. Basile, “The Semaphorin 4D-Plexin-B1-RhoA signaling axis recruits pericytes and regulates vascular permeability through endothelial production of PDGF-B and ANGPTL4,” Angiogenesis, vol. 17, no. 1, pp. 261–274, 2014.
- B. Aryal, N. Rotllan, E. Araldi et al., “ANGPTL4 deficiency in haematopoietic cells promotes monocyte expansion and atherosclerosis progression,” Nature Communications, vol. 7, Article ID 12313, 2016.
- A. Georgiadi, Y. Wang, R. Stienstra et al., “Overexpression of angiopoietin-like protein 4 protects against atherosclerosis development,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 33, no. 7, pp. 1529–1537, 2013.
- P. P. Hsu and D. M. Sabatini, “Cancer cell metabolism: Warburg and beyond,” Cell, vol. 134, no. 5, pp. 703–707, 2008.
- N. Hattori, E. Okochi-Takada, M. Kikuyama, M. Wakabayashi, S. Yamashita, and T. Ushijima, “Methylation silencing of angiopoietin-like 4 in rat and human mammary carcinomas,” Cancer Science, vol. 102, no. 7, pp. 1337–1343, 2011.
Copyright © 2017 Laura La Paglia et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.